NITER 2009

1 Treatments

Studied treatment

Control treatment

Concomittant treatments -

Age (years) 72 y

stent (%) 100%

cross over from the control arm to the catheter ablation arm 1.9%

MEn (%) 59.6%

2 Patients

Patients -

Inclusion criteria -

Exclusion criteria -

indication Resistant HTN with CRI

Diabetes (%) 61.6%

baseline serum cretinine (mg/dl) 1.7 mg/dl

History of hypertension (%) 96%

3 Methods

Blinding -

Design -

Centers -

Geographical area Italy

Sizes 28/24
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cause death</td>
<td>3/28</td>
<td>3/24</td>
<td>0,86</td>
<td>[0,16; 4,70]</td>
</tr>
<tr>
<td>Heart Failure</td>
<td>-/28</td>
<td>-/24</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Stroke</td>
<td>3/28</td>
<td>4/24</td>
<td>0,64</td>
<td>[0,13; 3,21]</td>
</tr>
<tr>
<td>Worsening renal failure</td>
<td>10/28</td>
<td>8/24</td>
<td>1,07</td>
<td>[0,34; 3,38]</td>
</tr>
<tr>
<td>Number of anti-hypertensive drugs at end of study</td>
<td>-/28</td>
<td>-/24</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References

Scarpioni R, Michieletti E, Pavone L, et al. Atherosclerotic renovascular disease (ARVD): medical therapy plus renal artery stenting (PRTS), compared with medical therapy alone, do not offer more chances in preventing C-V events or the progression of renal failure. Preliminary results of a prospective, multicenter and randomized trial Abstract World Congress of Nephrology; May 22, 2009; Milan, Italy; 2009. []